NewEdge Advisors’s Akero Therapeutics AKRO Stock Holding History

NewEdge Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7	Closed	-$201	–	3903
2024 Q3	$201	Hold	7	–	–	﹤0.01%	3682
2024 Q2	$164	Buy	+7	New	+$150	﹤0.01%	3662

Other funds holding AKRO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

NewEdge Advisors's AKRO Position: Q4 2024 in Review

NewEdge Advisors sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 7 shares — an estimated $201 sold.

NewEdge Advisors first reported a position in AKRO in Q2 2024 and held it in 2 quarters. The position peaked at $201 in Q3 2024. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

NewEdge Advisors reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
NewEdge Advisors sold 7 Akero Therapeutics shares in Q4 2024, an estimated $201.
NewEdge Advisors first reported a position in Akero Therapeutics in Q2 2024 and held it in 2 quarters.
NewEdge Advisors's Akero Therapeutics position peaked at $201 in Q3 2024.
191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.